274 related articles for article (PubMed ID: 20658156)
1. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease.
Park H; Shima T; Yamaguchi K; Mitsuyoshi H; Minami M; Yasui K; Itoh Y; Yoshikawa T; Fukui M; Hasegawa G; Nakamura N; Ohta M; Obayashi H; Okanoue T
J Gastroenterol; 2011 Jan; 46(1):101-7. PubMed ID: 20658156
[TBL] [Abstract][Full Text] [Related]
2. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease.
Nozaki Y; Fujita K; Yoneda M; Wada K; Shinohara Y; Takahashi H; Kirikoshi H; Inamori M; Kubota K; Saito S; Mizoue T; Masaki N; Nagashima Y; Terauchi Y; Nakajima A
J Hepatol; 2009 Sep; 51(3):548-56. PubMed ID: 19596472
[TBL] [Abstract][Full Text] [Related]
3. [The efficacy of ezetimibe on nonalcoholic fatty liver disease (NAFLD)].
Shiwa T; Kawanami Y; Yokoyama T; Moritani A; Hashimoto M; Gotoh T
Nihon Shokakibyo Gakkai Zasshi; 2011 Aug; 108(8):1383-92. PubMed ID: 21817841
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease.
Abel T; Fehér J; Dinya E; Eldin MG; Kovács A
Med Sci Monit; 2009 Dec; 15(12):MS6-11. PubMed ID: 19946244
[TBL] [Abstract][Full Text] [Related]
5. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial.
Takeshita Y; Takamura T; Honda M; Kita Y; Zen Y; Kato K; Misu H; Ota T; Nakamura M; Yamada K; Sunagozaka H; Arai K; Yamashita T; Mizukoshi E; Kaneko S
Diabetologia; 2014 May; 57(5):878-90. PubMed ID: 24407920
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy and safety of ezetimibe/simvastatin combination therapy in patients with type 2 diabetes and nonalcoholic fatty liver disease].
Abel T; Fehér J; Dinya E; Gamal Eldin M; Kovács A
Orv Hetil; 2009 May; 150(21):989-93. PubMed ID: 19443308
[TBL] [Abstract][Full Text] [Related]
7. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
Deushi M; Nomura M; Kawakami A; Haraguchi M; Ito M; Okazaki M; Ishii H; Yoshida M
FEBS Lett; 2007 Dec; 581(29):5664-70. PubMed ID: 18022391
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver.
Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
Med Hypotheses; 2006; 66(4):844-6. PubMed ID: 16188393
[TBL] [Abstract][Full Text] [Related]
9. Irisin in patients with nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
[TBL] [Abstract][Full Text] [Related]
10. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
[TBL] [Abstract][Full Text] [Related]
11. Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease?
Enjoji M; Nakamuta M
World J Gastroenterol; 2010 Feb; 16(7):800-3. PubMed ID: 20143458
[TBL] [Abstract][Full Text] [Related]
12. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease.
Enjoji M; Machida K; Kohjima M; Kato M; Kotoh K; Matsunaga K; Nakashima M; Nakamuta M
Lipids Health Dis; 2010 Mar; 9():29. PubMed ID: 20222991
[TBL] [Abstract][Full Text] [Related]
13. Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease.
Assy N; Grozovski M; Bersudsky I; Szvalb S; Hussein O
World J Gastroenterol; 2006 Jul; 12(27):4369-76. PubMed ID: 16865780
[TBL] [Abstract][Full Text] [Related]
14. The effect of ezetimibe on NAFLD.
Averna M
Atheroscler Suppl; 2015 Feb; 17():27-34. PubMed ID: 25659874
[TBL] [Abstract][Full Text] [Related]
15. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
16. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
Zheng S; Hoos L; Cook J; Tetzloff G; Davis H; van Heek M; Hwa JJ
Eur J Pharmacol; 2008 Apr; 584(1):118-24. PubMed ID: 18329014
[TBL] [Abstract][Full Text] [Related]
17. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet.
Chan DC; Watts GF; Gan SK; Ooi EM; Barrett PH
Diabetes Care; 2010 May; 33(5):1134-9. PubMed ID: 20185740
[TBL] [Abstract][Full Text] [Related]
18. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
[TBL] [Abstract][Full Text] [Related]
19. Ezetimibe prevents the development of non‑alcoholic fatty liver disease induced by high‑fat diet in C57BL/6J mice.
Wang X; Ren Q; Wu T; Guo Y; Liang Y; Liu S
Mol Med Rep; 2014 Dec; 10(6):2917-23. PubMed ID: 25310357
[TBL] [Abstract][Full Text] [Related]
20. Novel role of NPC1L1 in the regulation of hepatic metabolism: potential contribution of ezetimibe in NAFLD/NASH treatment.
Yoshida M
Curr Vasc Pharmacol; 2011 Jan; 9(1):121-3. PubMed ID: 21044016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
